Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434680 | 0.90 | GAA (0.62) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL7441139 | 0.87 | PLAU (0.45) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL7435763 | 0.82 | MAPT (0.55) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL7438222 | 0.81 | MCHR1 (0.52) | POLB | |
| SCHEMBL7444059 | 0.80 | MAPT (0.40) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL7436144 | 0.80 | THRB (0.40) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL14742925 | 0.80 | KMT2A (0.62) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL6687492 | 0.80 | MEN1 (0.62) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL7436552 | 0.80 | PTGS2 (0.45) | MEN1KMT2AALDH1A1PLAUMAPT | |
| SCHEMBL7433530 | 0.77 | RAB9A (0.49) | MEN1KMT2AALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507707-B2 | Methods of inducing ovulation using a non-polypeptide camp level modulator | LABORATOIRES SERONO SA (CH) | 2009-03-24 | — | — | US | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | claimed |
| EP-0506194-B1 | 4-aryl-thiazole or imidazole derivatives | AKZO NOBEL NV (NL) | 1996-08-21 | — | — | EP | claimed |
| US-5254575-A | 4-aryl-thiazole derivatives | AKZO N.V. (NL) | 1993-10-19 | — | — | US | claimed |
| EP-0506194-A1 | 4-aryl-thiazole or imidazole derivatives | Akzo Nobel N.V. (NL) | 1992-09-30 | — | — | EP | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | disclosed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0506194-B1 | 4-aryl-thiazole or imidazole derivatives | AKZO NOBEL NV (NL) | 1996-08-21 | — | — | EP | disclosed |
| US-5462959-A | 4-aryl-imidazole derivatives | AKZO N.V. (NL) | 1995-10-31 | — | — | US | disclosed |
| US-5254575-A | 4-aryl-thiazole derivatives | AKZO N.V. (NL) | 1993-10-19 | — | — | US | disclosed |
| EP-0506194-A1 | 4-aryl-thiazole or imidazole derivatives | Akzo Nobel N.V. (NL) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | MEN1 2633/4885KMT2A 3126/4885ALDH1A1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.